SCHEDULE: Armistice Capital Discloses 7.05% Stake in BioXcel Therapeutics

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7.05% of BioXcel Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC, along with Steven Boyd, has filed a Schedule 13G indicating beneficial ownership of 1,910,076 shares of BioXcel Therapeutics, Inc. common stock.
• This holding represents 7.05% of the class of securities.
• The filing date for this event is March 31, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership without specific commentary on the company's performance or future prospects.

Positives

• Armistice Capital, LLC has taken a significant stake, holding 7.05% of BioXcel Therapeutics, Inc. common stock, which could signal confidence in the company's future prospects.
• The filing indicates shared voting and dispositive power over 1,910,076 shares, suggesting active management and potential influence.

Negatives

• The Master Fund, the direct holder of the shares, disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which limits its voting and disposal powers.
• The filing does not provide details on the acquisition cost or strategy behind this stake.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.
• Potential for increased scrutiny from regulators or other investors due to the significant ownership stake.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's strategic interest in BioXcel Therapeutics within the biotechnology sector.

Stakeholder Impact

• Shareholders may see increased attention on BioXcel Therapeutics due to the significant stake held by Armistice Capital, potentially leading to increased volatility or strategic shifts.
• Management and the Board of Directors of BioXcel Therapeutics will be aware of the substantial ownership by Armistice Capital.

Next Steps

• Monitor future filings from Armistice Capital and Steven Boyd for any changes in their beneficial ownership.
• Observe BioXcel Therapeutics's strategic decisions and performance, which may be influenced by significant institutional holdings.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide sufficient information to make a buy or sell recommendation. It indicates a significant stake, suggesting potential for future engagement or influence, but without further performance data or strategic insights, a 'hold' is prudent for existing investors, while new investors should conduct further due diligence.

Keywords

Schedule 13G, BioXcel Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management